(Q43213496)

16 November 2017

Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen (English)

1 reference

16 November 2017

1 reference

Franck Bürki

1

1 reference

16 November 2017

Kattalin Badie

2

1 reference

16 November 2017

Philippe Bartoli

3

1 reference

16 November 2017

Pascale Bernard

4

1 reference

16 November 2017

Jean Louis Montastruc

5

1 reference

16 November 2017

Haleh Bagheri

6

1 reference

16 November 2017

language of work or name

English

0 references

publication date

15 February 2008

1 reference

British Journal of Clinical Pharmacology

16 November 2017

1 reference

16 November 2017

65

1 reference

16 November 2017

5

1 reference

16 November 2017

793-794

1 reference

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

16 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432493

Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432493

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432493

Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432493

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432493

Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432493

Reversible posterior leukoencephalopathy syndrome induced by sunitinib

15 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18279475

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Hypertension as a predictive factor of Sunitinib activity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18279475

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2125.2008.03119.X

1 reference

16 November 2017

1 reference

16 November 2017

PubMed publication ID

18279475

1 reference